• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Bayesian clinical trial design using historical data that inform the treatment effect.基于历史数据信息进行治疗效果推断的贝叶斯临床试验设计。
Biostatistics. 2019 Jul 1;20(3):400-415. doi: 10.1093/biostatistics/kxy009.
2
Bayesian design of a survival trial with a cured fraction using historical data.利用历史数据进行具有治愈部分的生存试验的贝叶斯设计。
Stat Med. 2018 Nov 20;37(26):3814-3831. doi: 10.1002/sim.7846. Epub 2018 Jun 25.
3
A novel power prior approach for borrowing historical control data in clinical trials.一种在临床试验中借用历史对照数据的新型功率先验方法。
Stat Methods Med Res. 2023 Mar;32(3):493-508. doi: 10.1177/09622802221146309. Epub 2023 Jan 4.
4
Critical appraisal of Bayesian dynamic borrowing from an imperfectly commensurate historical control.贝叶斯动态借用不完美匹配历史对照的批判性评价。
Pharm Stat. 2020 Sep;19(5):613-625. doi: 10.1002/pst.2018. Epub 2020 Mar 17.
5
Incorporating historical two-arm data in clinical trials with binary outcome: A practical approach.将二分类结局临床试验中的历史双臂数据纳入:一种实用方法。
Pharm Stat. 2020 Sep;19(5):662-678. doi: 10.1002/pst.2023. Epub 2020 Mar 30.
6
Bayesian semiparametric meta-analytic-predictive prior for historical control borrowing in clinical trials.贝叶斯半参数荟萃分析-预测先验在临床试验中对历史对照数据的借鉴。
Stat Med. 2021 Jun 30;40(14):3385-3399. doi: 10.1002/sim.8970. Epub 2021 Apr 13.
7
Bayesian design of noninferiority trials for medical devices using historical data.使用历史数据的医疗器械非劣效性试验的贝叶斯设计。
Biometrics. 2011 Sep;67(3):1163-70. doi: 10.1111/j.1541-0420.2011.01561.x. Epub 2011 Mar 1.
8
Bayesian sample size determination for a Phase III clinical trial with diluted treatment effect.针对具有稀释治疗效果的III期临床试验的贝叶斯样本量确定
J Biopharm Stat. 2018;28(6):1119-1142. doi: 10.1080/10543406.2018.1436556. Epub 2018 Mar 7.
9
Robust meta-analytic-predictive priors in clinical trials with historical control information.具有历史对照信息的临床试验中的稳健元分析预测先验。
Biometrics. 2014 Dec;70(4):1023-32. doi: 10.1111/biom.12242. Epub 2014 Oct 29.
10
Bayesian hypothesis testing with frequentist characteristics in clinical trials.临床试验中具有频率派特征的贝叶斯假设检验。
Contemp Clin Trials. 2019 Dec;87:105858. doi: 10.1016/j.cct.2019.105858. Epub 2019 Oct 24.

引用本文的文献

1
Control of Unconditional Type I Error in Clinical Trials With External Control Borrowing-A Two-Stage Adaptive Design Perspective.采用外部对照借用的临床试验中无条件I型错误的控制——两阶段自适应设计视角
Pharm Stat. 2025 May-Jun;24(3):e70011. doi: 10.1002/pst.70011.
2
Borrowing using historical-bias power prior with empirical Bayes.使用经验贝叶斯方法,借助具有历史偏差的先验进行借取。
J Biopharm Stat. 2024 Dec 8:1-31. doi: 10.1080/10543406.2024.2429461.
3
Protocol for the Catheter-Related Early Thromboprophylaxis With Enoxaparin (CRETE) Studies.依诺肝素导管相关早期血栓预防(CRETE)研究方案
Pediatr Crit Care Med. 2025 Jan 1;26(1):e95-e105. doi: 10.1097/PCC.0000000000003648. Epub 2024 Nov 20.
4
New clinical trial design borrowing information across patient subgroups based on fusion-penalized regression models.基于融合惩罚回归模型的亚组患者信息借用的新型临床试验设计。
Stat Methods Med Res. 2024 Oct;33(10):1718-1730. doi: 10.1177/09622802241267355. Epub 2024 Aug 19.
5
Bayesian Methods: A Means of Improving Statistical Power in Preclinical Neurotrauma?贝叶斯方法:提高临床前神经创伤统计效力的一种手段?
Neurotrauma Rep. 2024 Jul 16;5(1):699-707. doi: 10.1089/neur.2024.0028. eCollection 2024.
6
Using Bayesian statistics in confirmatory clinical trials in the regulatory setting: a tutorial review.在监管环境下的验证性临床试验中使用贝叶斯统计:教程综述。
BMC Med Res Methodol. 2024 May 7;24(1):110. doi: 10.1186/s12874-024-02235-0.
7
A Bayesian platform trial design with hybrid control based on multisource exchangeability modelling.基于多源可交换性建模的贝叶斯平台试验设计与混合对照。
Stat Med. 2024 May 30;43(12):2439-2451. doi: 10.1002/sim.10077. Epub 2024 Apr 9.
8
Case weighted power priors for hybrid control analyses with time-to-event data.具有事件时间数据的混合控制分析的案例加权功效先验。
Biometrics. 2024 Mar 27;80(2). doi: 10.1093/biomtc/ujae019.
9
When we shouldn't borrow information from an existing network of trials for planning a new trial.当我们不应该从现有的试验网络中借用信息来规划一项新试验时。
Front Pharmacol. 2023 Apr 27;14:1157708. doi: 10.3389/fphar.2023.1157708. eCollection 2023.
10
Development and Evaluation of a Simulation-Based Algorithm to Optimize the Planning of Interim Analyses for Clinical Trials in ALS.基于模拟的算法在 ALS 临床试验中期分析计划优化中的开发和评估。
Neurology. 2023 Jun 6;100(23):e2398-e2408. doi: 10.1212/WNL.0000000000207306. Epub 2023 Apr 21.

本文引用的文献

1
A Calibrated Power Prior Approach to Borrow Information from Historical Data with Application to Biosimilar Clinical Trials.一种校准功率先验方法:从历史数据中借用信息并应用于生物类似药临床试验
J R Stat Soc Ser C Appl Stat. 2017 Nov;66(5):979-996. doi: 10.1111/rssc.12204. Epub 2016 Dec 23.
2
Robust meta-analytic-predictive priors in clinical trials with historical control information.具有历史对照信息的临床试验中的稳健元分析预测先验。
Biometrics. 2014 Dec;70(4):1023-32. doi: 10.1111/biom.12242. Epub 2014 Oct 29.
3
Bayesian design of superiority clinical trials for recurrent events data with applications to bleeding and transfusion events in myelodyplastic syndrome.用于复发事件数据的优效性临床试验的贝叶斯设计及其在骨髓增生异常综合征出血和输血事件中的应用
Biometrics. 2014 Dec;70(4):1003-13. doi: 10.1111/biom.12215. Epub 2014 Jul 16.
4
Bayesian sequential meta-analysis design in evaluating cardiovascular risk in a new antidiabetic drug development program.贝叶斯序贯荟萃分析设计在评估新型抗糖尿病药物研发项目中的心血管风险。
Stat Med. 2014 Apr 30;33(9):1600-18. doi: 10.1002/sim.6067. Epub 2013 Dec 16.
5
Bayesian meta-experimental design: evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes.贝叶斯元实验设计:评估新型抗糖尿病疗法治疗2型糖尿病的心血管风险
Biometrics. 2012 Jun;68(2):578-86. doi: 10.1111/j.1541-0420.2011.01679.x. Epub 2011 Sep 28.
6
Hierarchical commensurate and power prior models for adaptive incorporation of historical information in clinical trials.用于在临床试验中自适应纳入历史信息的分层相称和幂先验模型。
Biometrics. 2011 Sep;67(3):1047-56. doi: 10.1111/j.1541-0420.2011.01564.x. Epub 2011 Mar 1.
7
Bayesian design of noninferiority trials for medical devices using historical data.使用历史数据的医疗器械非劣效性试验的贝叶斯设计。
Biometrics. 2011 Sep;67(3):1163-70. doi: 10.1111/j.1541-0420.2011.01561.x. Epub 2011 Mar 1.
8
Experience with reviewing Bayesian medical device trials.贝叶斯医疗器械试验的评审经验。
J Biopharm Stat. 2008;18(1):81-115. doi: 10.1080/10543400701668274.
9
Bayesian assessment of sample size for clinical trials of cost-effectiveness.成本效益临床试验样本量的贝叶斯评估
Med Decis Making. 2001 May-Jun;21(3):219-30. doi: 10.1177/0272989X0102100307.
10
Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.高危切除性皮肤黑色素瘤的干扰素α-2b辅助治疗:东部肿瘤协作组试验EST 1684
J Clin Oncol. 1996 Jan;14(1):7-17. doi: 10.1200/JCO.1996.14.1.7.

基于历史数据信息进行治疗效果推断的贝叶斯临床试验设计。

Bayesian clinical trial design using historical data that inform the treatment effect.

机构信息

Department of Biostatistics, University of North Carolina, McGavran-Greenberg Hall, CB#7420, Chapel Hill, NC, USA.

出版信息

Biostatistics. 2019 Jul 1;20(3):400-415. doi: 10.1093/biostatistics/kxy009.

DOI:10.1093/biostatistics/kxy009
PMID:29547966
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6587921/
Abstract

We consider the problem of Bayesian sample size determination for a clinical trial in the presence of historical data that inform the treatment effect. Our broadly applicable, simulation-based methodology provides a framework for calibrating the informativeness of a prior while simultaneously identifying the minimum sample size required for a new trial such that the overall design has appropriate power to detect a non-null treatment effect and reasonable type I error control. We develop a comprehensive strategy for eliciting null and alternative sampling prior distributions which are used to define Bayesian generalizations of the traditional notions of type I error control and power. Bayesian type I error control requires that a weighted-average type I error rate not exceed a prespecified threshold. We develop a procedure for generating an appropriately sized Bayesian hypothesis test using a simple partial-borrowing power prior which summarizes the fraction of information borrowed from the historical trial. We present results from simulation studies that demonstrate that a hypothesis test procedure based on this simple power prior is as efficient as those based on more complicated meta-analytic priors, such as normalized power priors or robust mixture priors, when all are held to precise type I error control requirements. We demonstrate our methodology using a real data set to design a follow-up clinical trial with time-to-event endpoint for an investigational treatment in high-risk melanoma.

摘要

我们考虑了在存在历史数据的情况下进行临床试验的贝叶斯样本量确定问题,这些数据可以提供有关治疗效果的信息。我们广泛适用的基于模拟的方法为校准先验的信息量提供了一个框架,同时确定了新试验所需的最小样本量,以便总体设计具有适当的能力来检测非零治疗效果和合理的 I 型错误控制。我们开发了一种全面的策略来获取零假设和替代抽样先验分布,这些分布用于定义贝叶斯对传统 I 型错误控制和功效概念的概括。贝叶斯 I 型错误控制要求加权平均 I 型错误率不超过预定阈值。我们开发了一种使用简单的部分借用功效先验生成适当大小的贝叶斯假设检验的程序,该先验总结了从历史试验中借用的信息量的分数。我们从模拟研究中得出的结果表明,当所有这些都符合精确的 I 型错误控制要求时,基于这种简单功效先验的假设检验程序与基于更复杂的荟萃分析先验(如归一化功效先验或稳健混合先验)的程序一样有效。我们使用真实数据集展示了我们的方法,以设计具有高风险黑色素瘤研究治疗的时间事件终点的后续临床试验。